New Study Aims to Increase Adoption of Advanced Diabetes Technology in Young People with T1D
JDRF Canadian Clinical Trial Network launches new clinical trial for children and adolescents living with type 1 diabetes
Ottawa, ON (November 3, 2011) – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the launch of the first multi-centre pediatric study in Canada using insulin pump therapy and continuous glucose monitoring (CGM). Based at the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa and led by JDRF CCTN researcher, Dr. Margaret Lawson, the study – Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes Trial (CGM TIME Trial) – will involve 128 children and teenagers aged five to 18 years old with type 1 diabetes (T1D). The goal of the study is to find better ways for youths to manage the disease and, in particular, determine the best times to introduce CGM usage among this age group.
CGM devices provide both a real-time snapshot of the glucose levels of a person with diabetes, as well as trend information on whether glucose is moving upwards or downwards, and how fast. The devices also provide warnings when the glucose is becoming too high or too low.
JDRF’s landmark CGM trials have shown that CGMs can significantly improve diabetes control and decrease the frequency of high and low blood sugars when used regularly. However, a significant number of children in the studies, and particularly teens and young adults, did not use the CGM devices consistently.
“While insulin pump therapy is popular amongst children, teens and their parents, the majority of pediatric pump users do not achieve adequate diabetes control, which means they are still at risk of developing diabetes-related complications in later years,” said Dr. Lawson, Pediatric Endocrinologist, CHEO. “What’s more, recent studies have shown that even testing blood glucose levels 10 times per day isn’t enough – and in the periods between testing, many children still experience highs and lows which affect their diabetes control and their sense of well-being. That’s why the CGM TIME trial is important, because we know CGMs can significantly help children and teens manage their diabetes more effectively when used with insulin pumps. We just need to determine at what point in their lives they will easily adopt the diabetes technologies.”
“More than three million Canadians live with some form of diabetes. This number is increasing by three to five per cent every year, and the greatest rise is in children five to nine years of age,” said Andrew McKee, President and CEO of JDRF Canada. “This study will explore how children with type 1 diabetes, their parents and their health care team can optimally manage their disease so that kids can have the best quality of life while preventing the onset of complications.”
The addition of CGM to pump therapy is central to the development of an artificial pancreas system – an automated closed loop system which will disperse insulin based on real-time changes in blood sugar levels. The artificial pancreas would enable people living with T1D to
maintain blood sugar levels within the normal range with minimal effort, resulting in better quality of life and lower risks of complications (www.artificialpancreasproject.com).
“The Government of Canada is proud to support this innovative diabetes research, which will lead to treatments that will benefit patients not only in Canada, but around the world,” said the Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). “Clinical trials, like Dr. Lawson’s at CHEO, are creating new jobs and keeping Southern Ontario at the forefront of world-class research and commercialization opportunities.”
The study is being led by CHEO with participation from four other Ontario pediatric diabetes centres: Markham Stouffville Hospital, the Children's Hospital at London Health Sciences Centre, The Hospital for Sick Children (SickKids) and McMaster Children’s Hospital.
JDRF is the worldwide leader for research to cure T1D. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. T1D is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with T1D have to test their blood sugar and give themselves insulin injections multiple times or use a pump – each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation.
Since its founding in 1970 by parents of children with T1D, JDRF has awarded more than $1.5 billion to diabetes research, including $107 million last year. For more information, please visit www.jdrf.ca.
About JDRF CCTN
Created in partnership with the Government of Canada, funding for JDRF CCTN came from a commitment of $20 million by FedDev Ontario, with an additional $13.9 million contribution from JDRF. The $33.9 million investment will help accelerate the testing of new technologies and treatments for Canadians and individuals around the world living with T1D and its complications. JDRF CCTN is a groundbreaking effort to accelerate solutions for the management, care and cure of T1D. JDRF CCTN is currently developing several high-profile clinical trials, in association with leading diabetes researchers at partner universities and medical centers in Southern Ontario. The goal is to position Southern Ontario as an international hub for diabetes translational research, innovation, and commercialization of new therapeutics and enabling technologies. For more information, please visit www.jdrf.ca/cctn.
For more information, please contact:
Jennifer McEvoy, JDRF CCTN
Carolyn Carson, Hill & Knowlton